1834 Investment Advisors Co. Grows Stock Position in Pfizer Inc. $PFE

Key Points

• 1834 Investment Advisors Co. increased its stake in Pfizer Inc. by 8.5% in Q2, owning a total of 297,765 shares valued at approximately $7.2 million.
• Several institutional investors, including Vanguard Group Inc. and Northern Trust Corp., also increased their holdings in Pfizer during the first quarter, collectively boosting the institutional ownership to 68.36%.
• Pfizer reported earnings of $0.78 per share for its latest quarter, exceeding analyst expectations, with revenue rising to $14.65 billion.

1834 Investment Advisors Co. grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 8.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 297,765 shares of the biopharmaceutical company's stock after acquiring an additional 23,360 shares during the quarter. 1834 Investment Advisors Co.'s holdings in Pfizer were worth $7,218,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after buying an additional 4,629,976 shares in the last quarter. Northern Trust Corp lifted its position in Pfizer by 6.8% during the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock worth $1,579,340,000 after buying an additional 3,943,397 shares in the last quarter. Amundi lifted its position in Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after buying an additional 15,758,846 shares in the last quarter. Invesco Ltd. lifted its position in Pfizer by 2.8% during the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock worth $767,709,000 after buying an additional 838,198 shares in the last quarter. Finally, Deutsche Bank AG lifted its position in Pfizer by 7.0% during the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock worth $715,581,000 after buying an additional 1,846,436 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 0.6%

NYSE:PFE opened at $23.75 on Friday. The stock has a 50-day simple moving average of $24.55 and a 200-day simple moving average of $24.14. The stock has a market cap of $135.03 billion, a P/E ratio of 12.63, a P/E/G ratio of 0.76 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the business earned $0.60 EPS. The business's quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research analyst reports. Morgan Stanley lifted their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Bank of America lifted their target price on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, September 20th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.